Id |
Subject |
Object |
Predicate |
Lexical cue |
T213 |
0-37 |
Sentence |
denotes |
Declaration of Conflicting Interests: |
T214 |
38-184 |
Sentence |
denotes |
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. |
T215 |
185-191 |
Sentence |
denotes |
J.N.A: |
T216 |
192-222 |
Sentence |
denotes |
Consultant for SK Lifescience. |
T217 |
223-229 |
Sentence |
denotes |
J.W.L: |
T218 |
230-335 |
Sentence |
denotes |
Cash compensation from Digitrace and Teladoc; grant from Enagage Therapeutics; co-founder of Soterya Inc. |
T219 |
336-342 |
Sentence |
denotes |
J.R.P: |
T220 |
343-389 |
Sentence |
denotes |
Stock ownership in Cognizance biomarkers, LLC. |
T221 |
390-396 |
Sentence |
denotes |
A.M.H: |
T222 |
397-814 |
Sentence |
denotes |
Editor for Journal of Clinical Neurophysiology; scientific advisory board or consultant for Marinus Pharmaceuticals, UCB Pharmaceuticals, Jazz Pharmaceuticals, Sage Therapeutics, Eisai Pharmaceuticals, and Neurelis Pharmaceuticals; royalties from Springer Publishers, Demos Medical Publishing, and Wolters Kluwer; research support from Marinus Pharmaceuticals, Sage Therapeutics, Biogen Idec, and UCB Pharmaceuticals. |